Rahul Bafna

It’s one of the greatest honors of my career to work with the team at AstraZeneca to use AI to make guideline-directed available to all patients. When my grandfather had lung cancer, life saving targeted therapies didn’t exist. Today, they do and it’s important that every patient can get access. One of the challenges of delivering Precision Medicine is the complexity and evolution of the best practice guidelines. Using AI technology to stay up-to-date with these advancements and to help ingest & structure the patient’s data in real-time makes it possible for all patients to be treated equitably. Tempus AI #healthequity American Society of Clinical Oncology (ASCO)

357

4 Comments

How do we minimize the number of protocol amendments and increase the operational feasibility of our clinical trials? This article below points out the benefits of using data, conversations and real world data to enhance the feasibility of the protocol design and inclusion/exclusion criteria: 1) Are we being too strict on our criteria in order to "control" for data variability? 2) Do are criteria allow for the intended patient population in the real world (if not, they need to) 3) How realistic is your design in how the study sites actually work? How they see and treat patients? How is your company ensuring the design meets these requirements? https://lnkd.in/gzJzFd-3

4

1 Comment

ArteraAI is at the 2024 American Society of Clinical Oncology (ASCO) annual meeting presenting 3 works on both our breast cancer and prostate cancer multi-modal AI (MMAI) tests. I'm stunned by our team's velocity - since founding the company about 2.5 years ago, we've produced about 30 scientific works forming the basis of our MMAI tests' evidence, largely with phase III clinical trials. Our breast cancer abstract demonstrates subgroup analysis of prognosis in HR+ HER2- early stage breast cancer. Our prostate cancer abstracts show the extension of our prostate test into oligo-metastatic and metastatic patients. This follows our recent oral presentation (https://lnkd.in/gkwhhEJf) at the 2024 American Urological Association (AUA) annual meeting, validating the first-ever AI biomarker that can stratify metastatic risk in patients with biochemical recurrence after surgery (radical prostatectomy), and in doing so predict therapeutic response to hormone therapy as an adjuvant to salvage radiation. ------- ASCO 2024 Evidence ------ Oral Presentation: Multimodal artificial intelligence models from baseline histopathology to predict prognosis in HR+ HER2- early breast cancer Poster Presentation: Validation of a digital pathology-based multimodal artificial intelligence model in oligometastatic castration-sensitive prostate cancer, including in patients from the STOMP and ORIOLE phase II randomized clinical trials. Poster Presentation: Prognostic validation of a digital pathology-based multi-modal artificial intelligence (MMAI) biomarker in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the CHAARTED trial (ECOG-ACRIN EA3805). #AI #MMAI #biomarkers #prostatecancer #breastcancer #arteraai #asco2024 #aua2024 https://lnkd.in/gTdRbUqQ

113

Cell & Gene therapy is a revolutionary field that has transformed the landscape of disease treatment and now sponsors are exploring alternative ways to study cell and gene therapies.

1

Come meet me at the upcoming GLP-1-Based Therapeutics Summit, where I'll be sharing insights on real-world GLP-1 prescribing trends gleaned from Truveta Data.  #GLP1Summit #GLP1 #PrescriptionTrends #PrescribingTrends 

2

Check out Jennifer Duff's interview on clinical trial tech challenges and solutions. Some key takeaways include the importance of adequate training and alignment of processes when integrating new tech to prevent disruptions. Additionally, assessing the necessity and impact of new technologies before adoption can save costs and align better with trial objectives. Decentralized Clinical Trials (DCTs) enhance flexibility and participant engagement, emphasizing the need for adaptable and participant-friendly technologies. AI and Machine Learning (ML) are improving trial processes like patient selection and data management, highlighting the importance of integrating these advancements into core systems for better outcomes. For more information about how Zelta by Merative is leading in tech implementation strategies in clinical trials, click the link below. #ClinicalTrials #HealthTech #DigitalTransformation #AIinHealthcare #DecentralizedClinicalTrials Merative Shannon Reilly

10

2 Comments

#transcript Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. Developing the drugs Vebreltinib and Uproleselan #RareDiseases #Cancer #LungCancer #Leukemias #BrainCancer #RareCancers #NextGenSequencing #MolecularProfiling #CancerMolecularProfiling #TumorMolecularProfiling Apollomics.com https://lnkd.in/gKSZaQAb

2

I started my career off in R&D, doing drug discovery research in oncology. I learned so much about the science of discovery, and the rigor that goes into developing, and eventually commercializing, breakthrough therapeutics. It’s a massive investment of time and resources – but in the nearly 30 years since I started my career in healthcare and healthtech, those breakthroughs have led to incredible improvements in patient outcomes across a wide range of therapy areas. It’s always inspiring to see how much innovation is still taking place in human therapeutics, and #ASCO2024 demonstrates how dramatically the industry continues to evolve. In particular, #RWE has unlocked an entirely new approach to patient-level Clinical, Commercial, and Outcomes insights that can help illustrate trends in care patterns, gaps in treatment, and spotlight patient populations that are otherwise left behind due to the limitations of the traditional process of clinical trial research. As Komodo’s recently Dr. Usha Periyanayagam, MD MPH said on our blog: “Pregnant women are excluded from so many facets of clinical research, which makes it even more important to utilize the real-world data available today to better understand this patient population.” I'm proud of our team at Komodo for our research into the experience and outcomes for pregnant women who have cancer. Learn more about our research at #ASCO2024 here:  https://lnkd.in/gFgDrqpg

73

Thank you to my fellow panelists (Asaf Evenhaim and Sneha Sharma), to our moderator Nadav Shimoni, M.D., and to the audience for the thoughtful discussion about AI and pharma commercialization. During the panel, we talked about our optimism AND our cautiousness around the use of AI, especially since we are still in the early days of good clinical and pharma use cases. For me, the focus remains not only on the quality of the data used to train AI models, but also on how we utilize our expertise to teach them. With appropriately developed models, we can more comfortably augment real world data to support commercialization while also designing future clinical trials. The key to developing accurate AI models, however, is to consider small language models (SLMs) as the basis. #SmallLanguageModels #SLM #TrainingAI

38

1 Comment

Exciting advancements are shaping the future of clinical trials! Recently interviewed Laurence P. Birch, CEO of Anju Software, on the critical role of AI and digital tech in research. Our discussion uncovered key insights on their integration and potential: - AI boosts data processing speed, vital for complex trials. - AI-led query management enhances communication and response times. - TA Scan Tool ensures diverse participant recruitment through advanced analysis. - Digital Health Technologies enable real-time monitoring and precise data collection. - Ethical focus on addressing AI biases and safeguarding patient autonomy and data privacy. These innovations are poised to revolutionize clinical trials, enhancing efficiency, diversity, and effectiveness in research. Read the full interview to explore more on AI and DCTs in the new era of clinical research. #ClinicalTrials #ArtificialIntelligence #DigitalHealth #HealthcareInnovation #ClinicalResearch #DiversityInResearch #PatientCare #HealthTech John F. Kouten

11

1 Comment

Lokavant, a clinical trial intelligence platform, has strengthened its team with the appointment of three new Advisory Board members and a new executive. The Advisory Board includes industry leaders like Pfizer’s Head of Predictive Analytics, Jonathan Crowther, who provide insights into the data and analytics needs of clinical trial sponsors and contract research organizations (CROs). Aaron Mackey, PhD, a former Covance executive, joins as senior vice president of AI and data science. Mackey brings expertise in artificial intelligence (AI) and data science to Lokavant, instrumental in advancing its technology and deriving novel insights. Lokavant’s Clinical Intelligence Platform utilizes data and predictive analytics to optimize clinical research outcomes. Despite the growing role of AI and increased data availability, life sciences face challenges harnessing data effectively for practical AI applications. Lokavant’s platform addresses this issue by aggregating and harmonizing data from multiple sources, enabling data scientists to analyze it effectively. This facilitates the identification of patterns and insights, empowering sponsors and CROs to make proactive decisions. Lokavant’s platform and predictive analytics address the challenges in the clinical research industry, leveraging data and AI to improve efficiency and accelerate the delivery of new therapies to patients.

3

🚀 **Calling All Clinical Development Leaders in Biopharma!** 🚀 Our industry is on the frontlines of innovation, yet we continue to grapple with some of the most **manual, time-consuming, and data-intensive** workflows. Let’s spotlight three critical areas that need our collective attention: 1. **Clinical Trial Sample Management** 🧪 Coordinating, tracking, and managing biological samples across multiple study sites can be incredibly daunting. The intricate manual logging processes and multi-step verifications drain valuable time and increase the risk of errors, delaying crucial insights and advancements. 2. **Patient Data Integration and Analysis** 📂 Integrating patient data from electronic health records (EHRs), laboratory systems, and wearable devices remains a herculean task. Manually curating and harmonizing diverse datasets for meaningful analysis not only consumes vast amounts of time but also limits our ability to unlock actionable insights swiftly. 3. **Regulatory Documentation Preparation** 📑 Preparing and maintaining comprehensive regulatory submissions involves mountains of paperwork, countless revisions, and excessive manual documentation. This painstakingly slow process hinders our ability to bring groundbreaking therapies to market without delay. These workflows demand **urgent innovation and automation**. By leveraging cutting-edge technologies like AI and machine learning, we can streamline these tasks, improve accuracy, and unleash the full potential of our teams. Let’s come together to drive change and champion efficiency in clinical development. Share your strategies, tools, and insights on how we can overcome these challenges and revolutionize our workflows. 💡 **Engage in the conversation and make an impact!** #ClinicalDevelopment #Biopharma #Innovation

2

❓ How is your company culture? ❓ What about its communication? ❓ And collaboration internally and externally? The writers of this two-part series contend that all three of the Cs are crucial to the success of clinical trials (and the companies themselves). With the guidance of part one, see how your trial/company stacks up. Then, follow up with part two, which provides pointers for developing and strengthening areas of weakness. Much thanks to Richard Malone, Tanisha Patel, Vincent Puglia, and Renee Riggs for lending their expertise! #clincialtrials #clinicalresearch

9

Interesting read on OncLive yesterday in collaboration with Dana-Farber Cancer Institute on cancer vaccines. Enjoyed hearing Dr Ott discuss the diverse clinical trials investigating vaccines in melanoma, SCC, RCC, bladder cancer, NSCLC, and pancreatic cancer. Will also be interesting to hear about new platforms including RNA-based and DNA-based vaccines! #cancer #oncology #precisionmedicine

11

“It’s all about the data” and a plethora of other advice on what is takes to secure #biotech funding in today’s environment from Rahul Ballal, Marian Nakada, Ph.D., Chong Xu, and Issi Rozen at MassBio’s #AlignSummit24, including: - have a clear - and realistic - plan to achieve clinical proof of mechanism - demonstrate operational execution by having and following a plan - recognize the risks and share the plan to derisk the assets and approach - understand that having data to derisk the asset is more important than building big teams and broad portfolios - before pitching to VCs, test the pitch with industry veterans to ensure the funding ask and timeframes are credible - embrace the resourcefulness and resilience of start ups - ensure a 2 year runway (because additional raises may take a year) - share with investors why the asset is important and how it impacts patients and their families - remain optimistic and keep going #venturecapital #IntentionalInvestments

30

1 Comment

What a fantastic event held by AWS and supporting companies. 2 big takeaways: 1) AI is rapidly changing to address issues and drive reliability with new tools from AWS and others. 2) Like any tool, you can't let this happen to you, you need to plan and apply it systematically for the benefit of your company. It was great to hear of the planned implementation and strategic alignment some companies are taking to best poise them for success.

1

Development of therapies is costly and challenging so many drop out leaving underserved patient communities without treatment. At #worldorphanusa Peter Marks, Director of the Center for Biologics Evaluation and Research talked about the need for removing barriers to keep researchers moving forward: -Unique production for small batch gene therapy -globalization of research approach to take varying regulatory requirements into consideration -streamlining process with the START program to get meetings in front of the FDA faster #onehavas making a #meaningfuldifference in #raredisease

23